NEXTBIOMEDICAL Enrolls First Patient in RESORB Trial of Nexsphere-F to Use it in Genicular Artery Embolization (GAE) for Knee Osteoarthritis

Shots:

• NEXTBIOMEDICAL has enrolled the first patient in the RESORB trial, evaluating Nexsphere-F vs intra-articular corticosteroid injections for use in GAE in ~126 US pts with painful knee osteoarthritis
• Nexsphere-F data from 155 pts published in The JVIR showed a 67% average pain reduction at 6mos., while a study published in The OJSM demonstrated safety & potential of transcatheter arterial embolization for patellar tendinopathy
• Nexsphere-F uses resorbable microsphere tech to temporarily block abnormal blood flow in pain-causing vessels, dissolving within 2–6hrs. to induce nerve-ending necrosis & provide rapid, lasting pain relief

Ref: Prnewswire | Image: NEXTBIOMEDICAL | Press Release

Related News:- NEXTBIOMEDICAL Secures the US FDA’s IDE Approval of Nexsphere-F to Use it in Genicular Artery Embolization (GAE) for Knee Osteoarthritis

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com